Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:MNMD 18 October 2025

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed shares hit a 52-week high of $13.09 on Oct. 14, up 68% year-to-date, after its LSD-derived drug MM120 showed 48% remission in a Phase 2b anxiety trial and received FDA Breakthrough Therapy status. The company holds $237.9 million in cash and is running three Phase 3 studies, with topline results due in 2026. Most analysts rate MNMD a “Moderate Buy” with an average 12-month target near $28.
18 October 2025
·
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Go toTop